This study is conducted to evaluate the efficacy of post-transplantation cyclophosphamide
with myeloablative or reduced-intensity conditioning regimen for allogeneic hematopoietic
cell transplantation (HCT) in patients with higher-risk myelodysplastic syndrome (MDS). The
efficacy of the treatment will be measured in terms of the GVHD-free, relapse-free survival.
The secondary end points of the study include engraftment, relapse incidence, non-relapse
mortality, graft-versus-host disease, donor chimerism, immune reconstitution, infections, and
survivals (overall and event-free).